Proactive antithyroid therapy improves survival in hyperthyroidism-induced liver injury: A real-world cohort study

Table 2 Comparison of baseline characteristics between antithyroid drug-induced liver injury patients with antithyroid drug exposure and those without antithyroid drug exposure, n (%)/median (interquartile range)

Items	Total (n = 140)	ATD (-) (n = 40)	ATD (+) (n = 100)	P value
Demographic characteristics
Age (years)	43 (35.1, 50.9)	45 (37.3, 52.8)	41 (31.2, 49.2)	0.062
Male	53 (37.9)	17 (42.5)	36 (36.0)	0.601
BMI (kg/m2)	22.6 (18.3, 25.6)	21.6 (18.1, 24.9)	23.5 (19.6, 25.9)	0.082
Non-drinkers	102 (72.9)	28 (70.0)	74 (74.0)	0.786
Length of hospital stay	20 (11, 32)	25 (15, 36)	18 (10, 28)	0.015
Number of hospitalizations in the past year				0.542
0	89 (63.6)	24 (60.0)	65 (65.0)	0.536
1	33 (23.6)	8 (20.0)	25 (25.0)	0.462
≥ 2	15 (10.7)	4 (10.0)	11 (11.0)	0.824
In-hospital medical costs (CNY)	38006 (15242, 43220)	45120 (38217, 48320)	33319 (12286, 39113)	0.021
Clinical presentation
Hepatic injury symptoms	123 (87.9)	34 (85.0)	89 (89.0)	0.428
Hyperthyroid symptoms	108 (77.1)	28 (70.0)	80 (80.0)	0.218
Ascites	28 (20)	7 (17.5)	21 (21.0)	0.310
Hepatic encephalopathy	17 (12.1)	6 (15.0)	11 (11.0)	0.318
Hyperthyroid heart disease	11 (7.8)	3 (7.5)	8 (8.0)	0.612
Prognostic score
ALBI	0.13 (-0.79, 0.27)	0.15 (-0.52, 0.31)	0.10 (-1.03, 0.20)	0.221
Child-Pugh	10.2 (8.9, 12.8)	10.3 (9.0, 13.1)	9.8 (8.1, 11.4)	0.620
MELD	20.6 (15.4, 25.2)	21.8 (16.6, 26.7)	19.4 (12.6, 23.2)	0.102
MELD-Na	22.5 (17.4, 27.6)	24.5 (18.5, 28.2)	20.8 (14.1, 25.6)	0.185

BMI: Body mass index; ALBI: Albumin-Bilirubin Index; MELD: Model for end-stage liver disease; ATD: Antithyroid drug.